There's no argument, I'm just stating facts. Minus the available funds, the MC is $60M right now and that's with 5 IP without any negative clinical trial updates released given all their development.
I've always said, the catalyst will be the further positive clinical trial update for VAXINIA and then positive clinical trial update for OASIS. These are the IP the market is interested and understandably given the market potential of them, they haven't value Azer-Cel at all right now. Hence, why IMU is very undervalue right now. The bear are only correct now as IMU hasn't released these clinical trial yet.
IMU Price at posting:
2.8¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)